Human neutrophil peptides upregulate expression of COX-2 and endothelin-1 by inducing oxidative stress

Farisa Syeda,1,2,3,4 Elizabeth Tullis,1,4 Arthur S. Slutsky,1,3 and Haibo Zhang1,2,3,4

1The Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital; and 2Departments of Anaesthesia and Physiology, 3Interdepartmental Division of Critical Care Medicine, and 4Division of Respiratory Medicine, University of Toronto, Toronto, Ontario, Canada

Submitted 28 February 2008; accepted in final form 21 April 2008


Elevated levels of HNPs in septic patients suggest that HNPs may play a critical role in the leukocyte-dominant proinflammatory responses that can contribute to cardiovascular disorders (2, 13, 27).

The vascular endothelium actively participates in maintaining vascular homeostasis by balancing vasoactive compounds between endothelium-derived relaxing and contracting factors. The major vasoactive by-products include prostaglandins, nitric oxide (NO), and endothelin-1 (ET-1).

Prostaglandins are produced following the sequential oxidation of arachidonic acid by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin synthases. COX-1 is responsible for the constitutive levels of prostaglandins, whereas COX-2 produces inducible prostaglandins in scenarios of inflammation through the stimulation of endothelial cells by various growth factors and cytokines (38). The major vasodilatory prostaglandin E2 (PGE2) is generated by catalyzing prostaglandin E synthases on prostaglandin H2 (PGH2). Similarly, prostacyclin (PGI2) synthase converts PGH2 into PGI2. PGE2 and PGI2 also exert anti-inflammatory properties (44).

ET-1, produced mainly by endothelial cells, is a potent vasoconstrictor by interaction with two key receptor types, endothelin receptors types A (ETA) and B (ETB). ETA receptors are found on the smooth muscle cells of blood vessels, and ETB is primarily located on the endothelial cells. Binding of ET-1 to the receptors increases vasoconstriction and the retention of sodium (15). ET-1 is reportedly associated with the pathogenesis of atherosclerosis (11).

It has been recently established that inflammation plays a crucial role in mediating all stages of atherosclerosis from initiation through progression (24). During leukocyte-dominated inflammatory responses, PMNs release large amounts of HNPs into the extracellular milieu. In turn, HNPs stimulate cells to produce ROS (31). The latter is known to modulate the expression of COX-2 and ET-1 in endothelial cells (5, 17). In the present study, we tested and proved the hypothesis that HNP-enhanced expression of COX-2 and ET-1 in endothelial cells through ROS-dependent mechanisms.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
METHODS

Reagents. Anti-COX-1 and COX-2 polyclonal antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal anti-β-actin antibodies, N-acetyl-l-cysteine (NAC), were obtained from Sigma (St. Louis, MO). Phospho- and total-p38 MAPK antibodies were from Cell Signaling Technology (Danvers, MA), and horseradish peroxidase-conjugated anti-goat and anti-rabbit antibodies were from Jackson ImmunoResearch (West Grove, PA). The selective inhibitors of U-0126 against mitogen-activated protein kinase kinase 1/2 (MEK1/2), SB-203580 against p38 mitogen-activated protein kinase (p 38 MAPK), and PG-490 (triptolide) and 4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine (JSH-23) against nuclear factor-κB (NF-κB), respectively, were purchased from Calbiochem (La Jolla, CA). Enhanced chemiluminescence kit was from PerkinElmer (Boston, MA). The purification of HNP has been previously described (20, 42).

Cell culture. Human umbilical vein endothelial cells (HUVECs, Cell Applications, San Diego, CA) were cultured in HUVEC medium (Cell Applications) at 37°C in a 5% CO2-95% room air. The cells were used on passage 2.

Western blot analysis. Confluent HUVECs in 30-mm2 dishes (Corning Costar, Cambridge, MA) were deprived of serum for 12–16 h and subjected to HNP stimulation. The cells were then lysed in a buffer containing 63.5 mM Tris-HCl (pH 6.8), 10% (vol/vol) glycerol, 2% (wt/vol) SDS, 1 mM Na3VO4, 1 mM 4-(2-aminoethyl)benzene sulfonyl fluoride, and 50 μg/ml leupeptin. Cell extracts were subject to SDS-PAGE and transferred to nitrocellulose membrane (Bio-Rad, Hercules, CA). Nonspecific antibody binding was blocked by the incubation of membranes in 50 mM Tris, 150 M NaCl, and 0.02% (vol/vol) Tween 20, pH 7.4 (TBST), containing 5% milk for 2 h. Membranes were subsequently incubated with the appropriate primary antibody in TBST/10% BSA. After being extensively washed with TBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies. Membranes were washed and signals were visualized with an enhanced chemiluminescence detection system (ECL Kit; PerkinElmer). The band density was determined by a Kodak image station 2000 MM (Mandel Scientific, Guelph, ON, Canada).

Measurement of PG12, PGE2, and ET-1. Upon completion of the experiments, the cell culture medium was collected and centrifuged at 112 g for 5 min. The cell culture supernatants were assayed for 6-keto-PGF-1α, a stable intermediate of PG12, using an ELISA kit (GE Healthcare, Buckinghamshire, UK). Levels of PGE2 (GE Healthcare) and ET-1 were measured by ELISA kits (R&D Systems, Minneapolis, MN).

Nitrotyrosine assay. Nitrotyrosine levels were detected in cell culture supernatants by using a commercial kit (Bioxytech Nitrotyrosine-EIA, Oxis International, Portland, OR).

Cytotoxicity measurement. To confirm the excellent cell viability in the conditions where HNP and/or the inhibitors were present, lactate dehydrogenase activity was measured at 490 nm (Cytotoxicity detection kit, Roche Applied Science, Penzberg, Germany) in all experiments.

Statistical analysis. Data are presented as means ± SD. Data were analyzed in nonparametric tests by using Prism GraphPad 4.0 software package (Prism, San Diego, CA). A comparison among groups was performed by ANOVA using the Kruskal-Wallis test. A P < 0.05 was considered as significant.

RESULTS

HNP increased the expression of COX-2 by the activation of p38 MAPK, ERK1/2, and NF-κB. HUVECs (1 × 106 cells) were stimulated with HNPs at 5 and 25 μg/ml for 4, 6, and 8 h, respectively. The cell viability measured by lactate dehydrogenase assays was not changed at the doses of HNPs used compared with the vehicle control group over time (data not shown). A time- and dose-dependent increase in COX-2 expression was observed, whereas the expression of COX-1 remained unchanged in response to HNP stimulation (Fig. 1A).

Fig. 1. Human neutrophil peptides (HNPs) increased expression of cyclooxygenase (COX)-2 by activation of p38 MAPK, ERK1/2, and NF-κB. A: confluent human umbilical vein endothelial cell (HUVEC) monolayers were incubated overnight with serum-free medium and exposed to either 0.01% acetic acid as vehicle control or HNPs. B and C: cells were treated with either vehicle (DMSO alone), SB-203580 (10 μM), U-0126 (10 μM), 4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine (JSH-23; 10 μM), or PG-490 (70 nM) for 30 min before stimulation with HNPs (25 μg/ml) for additional 6 h. Cells were lysed for Western blot analysis. Representative blots are illustrated from 3 independent experiments. The bar graphs present densitometric analysis of 3 experiments. *P < 0.05 vs. vehicle controls, respectively; †P < 0.05 vs. the immediate previous group; and ‡P < 0.05 vs. HNPs alone at identical conditions, respectively.
We next showed that the HNP-induced COX-2 expression was completely blocked by the inhibition of p38 MAPK and largely attenuated by the inhibition of MEK1/2 at the dose used (Fig. 1B). Since COX-2 expression is possibly mediated by NF-κB (8) and since we have previously demonstrated that the stimulation of epithelial and CD4+ T cells with HNP induced NF-κB translocation (42), we thus examined the role of NF-κB on the HNP-induced COX-2 expression by using the inhibitors JSH-23 and PG-490 (Triptolide) in HUVECs. The two compounds have been widely used as NF-κB inhibitors in in vivo and in vitro conditions (6, 8, 34, 36). We observed a significant attenuation of the HNP-induced COX-2 expression by using the NF-κB inhibitors (Fig. 1C).

HNPs had no significant effects on COX-2 activity and production of PGI2. Production of PGE2 has been used as an index of COX-2 activity (12). The COX-2 activity was not significantly altered after HNP stimulation although the level of PGI2 tended to increase in the cell culture medium (Fig. 2, A and B). We also stimulated the cells with IL-1α as a positive control (9) to ensure that the cells were able to increase COX-2 activity and the production of PGI2 (Fig. 2, A and B).

HNPs increased ET-1 release by activation of p38 MAPK, ERK1/2, and NF-κB. Since ET-1 is a major vasoconstrictor produced by endothelium, we measured the concentration of ET-1 that is produced independent of the COX-2 pathway. We observed a significant increase in ET-1 release as early as 30 min, followed by a time-dependent increase in response to HNP stimulation at a dose of 25 μg/ml (Fig. 3A). Stimulation with HNPs at a dose lower than 25 μg/ml for 8 h had no effects on ET-1 production (Fig. 3B). The HNP-induced ET-1 expression was significantly reduced by the use of inhibitors against p38 MAPK, ERK1/2, and NF-κB, respectively (Fig. 3C).

HNPs induced COX-2 and ET-1 through oxidative stress. ROS have been reported as key mediators to induce production of COX-2 (5, 17) and ET-1 (5, 18). We have previously reported that HNPs stimulate lung tissue to produce hydrogen peroxide (31). We thus measured the concentration of nitrotyrosine in HUVEC culture medium after HNP stimulation. Nitrotyrosine is a marker of peroxynitrite formation as a result of the generation of NO and superoxide (16). We observed that the stimulation of HUVECs with HNPs at 25 μg/ml resulted in a fourfold and 2.5-fold increase in nitrotyrosine levels at 30 min and 4 h, respectively (Fig. 4). When the antioxidant NAC was used to inhibit the HNP-induced oxidative stress, we observed a decrease in the expression of both COX-2 and ET-1 (Fig. 5, A and B) associated with an attenuation of p38 MAPK phosphorylation (Fig. 5C). Taken together, these results sug-
suggest that the HNPs induced an increase in the expression of COX-2 and ET-1 through oxidative stress.

**HNPs had no effects on angiotensin II to modulate COX-2 and ET-1.** A large body of evidence supports a role of angiotensin II in the modulation of the expression of COX-2 and ET-1 (5, 17, 40). We thus examined the angiotensin II pathway in the HNP-induced expression of COX-2 and ET-1 by using the dicarboxylate-containing angiotensin-converting enzyme inhibitor enalapril. Our results showed no effects on the HNP-induced expression of COX-2 or ET-1 by using enalapril at a dose of 100 μM (Fig. 6, A and B).

**DISCUSSION**

A main finding of our study is that HNPs can stimulate human endothelial cells to increase the expression of COX-2 and ET-1, and ROS play an important role in mediating the HNP-induced activation of endothelial cells. The treatment of endothelial cells with the ROS scavenger NAC attenuated the elevated expression of COX-2 and ET-1 in response to HNP stimulation.

Previous in vivo and in vitro studies have described the role of ROS and peroxynitrite in the regulation of COX-2 expression (21, 22). We have demonstrated that exposure of lung explants to HNPs resulted in an increase in the hydrogen peroxide production (31). We now observe an increased formation of nitrotyrosine that reflects the interaction between NO and ROS by human endothelial cells in response to HNP stimulation. Furthermore, the HNP-induced COX-2 expression was attenuated by the treatment with NAC. This observation indicates that HNPs increased COX-2 expression through oxidative stress. Previous studies have reported that an upregulation of COX-2 after stimulation with cytokines, thrombin, and growth factors usually led to an increased production of PGI2 in HUVECs (29, 36). However, the production of the prostaglandins PGI2 and PGE2 was not significantly altered despite an elevated COX-2 expression after HNP stimulation in our study. Interestingly, previous studies have also reported an absence of prostaglandin release despite an elevated COX-2 expression following the stimulation with NO donors (10, 32). A couple of mechanisms may explain the paradox of an increased COX-2 expression with the lack of prostaglandin production. Peroxynitrite can cause tyrosine nitration of COX, leading to the inactivation of COX activity (39). Peroxynitrite can also act as a potent inhibitor of PGI synthase, a terminal enzyme in PGI2 biosynthesis (7). It is noteworthy that we...
examined only PGI2 and PGE2 because they are the most characterized prostaglandins. The effects of HNP on other prostaglandins remain yet to be determined.

ET-1 is a dominant vasoconstrictor produced by endothelial cells (19, 26). We observed a rapid increase in ET-1 release as early as 30 min after HNP stimulation in HUVECs. The early and sustained expression of ET-1 could be due to autocrine regulatory properties by which ET-1 acts on cell surface receptors that in turn activates cells releasing more ET-1 (26). In addition, the HNP-induced oxidative stress at 30 min, as reflected by the formation of nitrotyrosine, resulted in the production of ET-1 that was blocked by the treatment of the cells with NAC. Our results are consistent with other studies reporting that ROS play an important role to stimulate smooth muscle cells (18) and endothelial cells (19), producing ET-1 in vitro and in vivo conditions (14, 45). It is noteworthy that the level of ET-1 expression in the NAC-treated group following HNP stimulation is somewhat lower than the nonstimulated or the NAC alone groups. This might suggest that some factors other than the ROS-dependent mechanism play a partial role in the HNP-induced ET-1 expression.

To understand the intracellular signaling mechanisms by which HNPs upregulated the expression of COX-2 and ET-1, we examined several signaling pathways including p38 MAPK, ERK1/2, and NF-κB since we have previously demonstrated that the kinases and NF-κB are involved in the modulation of adhesion molecules and IL-8 by monocytes and CD4+ cells in response to HNP stimulation (37, 42). By employing the specific inhibitors, we observed that p38 MAPK, ERK1/2, and NF-κB signaling pathways are required to modulate the HNP-induced expression of COX-2 and ET-1 in HUVECs. Other studies have demonstrated that the kinases and NF-κB signaling are required in the regulation of COX-2 and ET-1 in response to a variety of stimuli (23, 35).

The release of ET-1 was increased as short as 30 min, whereas COX-2 expression was upregulated at 4 h or later after HNP stimulation. In addition, the inhibitors of kinases and NF-κB were involved in the expression of ET-1 and COX-2. Taken together, these observations suggest that the early release of ET-1 may be responsible for the late increased COX-2 release expression, which is consistent with a study demonstrating that the activation of p38 MAPK is involved in endothelin-1-stimulated COX-2 expression in cultured endothelial smooth muscle cells (35).

It has been suggested that angiotensin II modulates COX-2 and ET-1 expression (5, 17). We did not observe any significant effects of the angiotensin-II pathway on the HNP-induced COX-2 or ET-1 expression in HUVECs by using enalapril, an inhibitor of angiotensin-converting enzyme. Unlike other angiotensin-converting enzyme inhibitors, enalapril does not interfere with the NO and ROS pathways (33). Taken together, these studies further support the central role of ROS by which HNPs activate endothelial cells.

In summary, we demonstrate that HNPs increased COX-2 and ET-1 expression in endothelial cells via ROS-dependent mechanisms associated with the activation of p38 MAPK, ERK1/2, and NF-κB signaling pathways. The effects of HNPs in the modulation of the course of cardiovascular diseases are yet to be elucidated in vivo conditions.

ACKNOWLEDGMENTS
F. Syeda is a recipient of Keenan Collaborative Project Fellowship of St. Michael’s Hospital. H. Zhang is a recipient of Ontario Premier’s Research Excellence Award.

GRANTS
This study was supported by Canadian Institutes of Health Research Grants CIHRMOP8558 and MOP69042 (to A. S. Słutsky and H. Zhang) and an Ontario Thoracic Society grant-in-aid (to H. Zhang).

REFERENCES

AJP-Heart Circ Physiol • VOL 294 • JUNE 2008 • www.ajpheart.org


